Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 15.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Mega-Chance im Tech-Sektor +++ Konkurrenz tief beeindruckt +++ Aktie noch günstig
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0J30B ISIN: BE0003846632 Ticker-Symbol: TG4 
Frankfurt
15.10.19
09:06 Uhr
2,595 Euro
+0,010
+0,39 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OXURION NV Chart 1 Jahr
5-Tage-Chart
OXURION NV 5-Tage-Chart
RealtimeGeldBriefZeit
2,590
2,670
18:33

Aktuelle News zur OXURION Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiOxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco179Poster Presentation Featuring Positive Topline data from Phase 1 Trial Evaluating THR-149, a novel, potent plasma kallikrein inhibitor for DME Leuven, Belgium , 9 October 2019 - 7.30 AM CET - Oxurion...
► Artikel lesen
09.09.Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME181Immediate onset of action - starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149.Prolonged...
► Artikel lesen
05.09.Oxurion NV Business Update - H1 2019239Positive Topline Phase 1 Results with THR-149 (Plasma Kallikrein Inhibitor) for treatment of DME Mixed Topline Results from exploratory THR-317 (anti-PlGF) Phase 2a ranibizumab combination...
► Artikel lesen
Börsennews zur OXURION Aktie und weiteren Hot Stocks erhalten
04.09.Oxurion NV: Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)191Company on Track for Data Read Out by End of 2019 Leuven, Belgium, 4 September 2019 - 7.30 AM CET- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments...
► Artikel lesen
02.09.Oxurion NV: Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019184Further preclinical and clinical data presentations of its other diabetic eye disease clinical candidates, THR-687 (Pan-RGD Integrin Inhibitor) and THR-317 (anti-PlGF), will also be delivered Leuven...
► Artikel lesen
20.08.Oxurion's THR-317 flunks mid-stage DME study, shares down 31%5
20.08.BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME263LUND, Sweden, Aug. 20, 2019 /PRNewswire/ -- BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase lla study evaluating THR-317,...
► Artikel lesen
20.08.Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME267Combination therapy did not show increase in BCVA in the overall population at Month 3.Certain improvement in mean BCVA at Month 3 observed with the combination therapy in 2 pre-specified subgroups:...
► Artikel lesen
01.07.Bicycle Therapeutics Announces Positive Topline Results from Oxurion's Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema75Phase I results provide additional clinical activity data for Bicycles Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide...
► Artikel lesen
01.07.Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment63Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported.Rapid onset of action starting at Day 1 with increasing...
► Artikel lesen
11.06.Oxurion NV: ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies50Leuven, Belgium 11 June 2019 - ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today announces that it has received from Flanders Innovation...
► Artikel lesen
06.06.Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting70Leuven, Belgium, 6th June 2019 - 7 PM CET - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients...
► Artikel lesen
08.05.Oxurion NV: Oxurion NV Business Update - Q1 201931Oxurion NV Business Update - Q1 2019 Significant Progress with Novel Clinical Diabetic Eye Disease Portfolio Enrollment of THR-317 Phase 2 Combination Study & THR-149 Phase 1 Study Completed...
► Artikel lesen
24.04.Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema43Oxurion Study of THR-149 Enrolls Early with 15 DME Patients Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic...
► Artikel lesen
24.04.Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule27Leuven, Belgium, 24 April 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with...
► Artikel lesen
04.04.Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule32Leuven, Belgium, April 4th 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with...
► Artikel lesen
07.03.Oxurion NV Business Update - FY 201826Significant Progress with Novel Diabetic Eye Disease Portfolio Positive Topline Results from Phase 1/2 evaluating THR-317 for treatment of DME Multiple Clinical Readouts Expected towards...
► Artikel lesen
28.02.Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting22Leuven, Belgium, 28 February 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients...
► Artikel lesen
04.02.Oxurion NV to Present at the 2019 BIO CEO & Investor Conference25Leuven, Belgium, 4 February 2019 - Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with...
► Artikel lesen
19.12.18Oxurion NV to Present at 2019 Biotech Showcase[TM] Conference and Participate in CEO Power Breakfast Roundtable During the 37th Annual J.P. Morgan Healthcare Conference20LEUVEN, Belgium, December 19, 2018 /PRNewswire/ -- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1